TW's Take: as usual, the biggest knock on this company was expectations of a financing. With this very large deal over, LTRN is now positioned to execute on their strategy. With LP-184 getting closer to an IND filing later...
Nothing seems to be able to get in the way of this bull market. An insurrection in DC? Yawn. The next administration taking on big tech? Nobody cares. Covid-19 running crazy globally? That just means more stimulus and Robin...
TW's Take: we are very excited about this. ADC's are proving to be very effective and also companies focused on this space are in high demand at premium valuations. This should reflect well on the share price of Lantern...
If you position yourself for success, sometimes you get lucky, right? It’s become common knowledge that A.I. is changing the way all companies do business, but Lantern Pharma was an early adopter in understanding the potential of A.I. in...
TW's Take: Hopkins is the world leader in GBM. This announcement means that there are now three leading research institutes working with LP-184 on different cancers. LP-184 has the potential to be a blockbuster drug for Lantern Pharma. DALLAS, Dec....
Tailwinds' Take: LP-184 is proving to be a very valuable drug for fighting multiple types of cancer, especially as a co-therapy with the standard of care. GBM is a particularly deadly disease and showing benefits here would be outstanding...
November was truly a month to remember for the markets. The best month in over 40 years for the Russell 2000 saw that index climb a whopping 18%. This outpaced the S&P and Nasdaq as smaller companies are really...
Panna Sharma: Thank you Marek, and good afternoon to everyone on the call today. Thank you for joining us for our third quarter 2020 conference call. A few moments ago we issued a press release at 4:00 PM, highlighting both...
What do I want to say? That's the question that comes into my head every Saturday morning. This newsletter is an opportunity. An opportunity to send a message to thousands of readers. It's a privilege that I don't take...
Tailwinds' Take: crossing a billion datapoints is a big goal achieved ahead of schedule. The platform being developed by Lantern is getting more powerful and expect to hear a lot more about new drug opportunities and combination therapies on...
Tailwinds' Take: LP-184 has great potential as this collaboration with a leading research institute demonstrates. LTRN's unique AI capabilities have the potential to be revolutionary for product development in oncology. DALLAS , Oct. 5, 2020 /PRNewswire/ -- Lantern Pharma (NASDAQ: LTRN), a clinical stage biopharmaceutical...
Like the debate, 2020 has been a sh**-show. Pandemics, political divisiveness, fires...it's not been a beach party to say the least. Yet, here we stand at the end of Q3 with the S&P having climbed 8.5% in the quarter and...
Markets were very volatile this past week, trading back and forth like a game of ping-pong. There's little doubt in my mind that the pickup in volatility of the last few weeks will remain here through the election, if...
Tailwinds' Take: LTRN will benefit greatly from this partnership through development of LP-184 and gobs more data for their machine learning process. This quote from the CEO sums up not only the benefits to the Company, but how Lantern...
The easiest way to make money in the market is trading off of insider information. It is also highly illegal, will put you in jail and I really don't recommend it. It's effective in the short term, but truly...
Today we are initiating coverage of Lantern Pharma (LTRN). Lantern is a clinical stage biopharmaceutical company that uses artificial intelligence, advanced machine learning, genomics, and big data to personalize cancer treatment therapies—and improve patient outcomes. Lantern identifies late-stage drugs with...
DALLAS, Aug. 27, 2020 /PRNewswire/ -- Lantern Pharma (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR^® artificial intelligence ("A.I.") platform to transform the pace, risk and cost of oncology drug discovery and development, and identify patients who will benefit from...
DALLAS, July 30, 2020 /PRNewswire/ -- Lantern Pharma (NASDAQ: LTRN), a clinical stage biotechnology company using its proprietary RADR® artificial intelligence ("A.I.") platform to improve drug discovery and development, and identify patients who will benefit from its portfolio of targeted oncology therapeutics, today...
DFC Advisory Services LLC (dba Tailwinds Research) is a registered investment adviser. Information presented is for educational purposes only and does not intend to make an offer or solicitation for the sale or purchase of any specific securities, investments, or investment strategies. Investments involve risk and unless otherwise stated, are not guaranteed. Be sure to first consult with a qualified financial adviser and/or tax professional before implementing any strategy discussed herein. Past performance is not indicative of future performance.